NTLA
Income statement / Annual
Last year (2025), Intellia Therapeutics Inc's total revenue was $67.67 M,
an increase of 16.92% from the previous year.
In 2025, Intellia Therapeutics Inc's net income was -$412.69 M.
See Intellia Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$67.67 M |
$57.88 M |
$36.28 M |
$52.12 M |
$33.05 M |
$57.99 M |
$43.10 M |
$30.43 M |
$26.12 M |
$16.48 M |
| Cost of Revenue |
$15.92 M
|
$10.29 M
|
$8.98 M
|
$7.57 M
|
$6.89 M
|
$150.41 M
|
$108.41 M
|
$89.12 M
|
$67.65 M
|
$31.84 M
|
| Gross Profit |
$51.75 M
|
$47.59 M
|
$27.30 M
|
$44.55 M
|
$26.16 M
|
-$92.41 M
|
-$65.31 M
|
-$58.68 M
|
-$41.53 M
|
-$15.36 M
|
| Gross Profit Ratio |
0.76
|
0.82
|
0.75
|
0.85
|
0.79
|
-1.59
|
-1.52
|
-1.93
|
-1.59
|
-0.93
|
| Research and Development Expenses |
$388.86 M
|
$466.31 M
|
$435.07 M
|
$419.98 M
|
$229.81 M
|
$150.41 M
|
$108.41 M
|
$89.12 M
|
$67.65 M
|
$31.84 M
|
| General & Administrative Expenses |
$119.80 M
|
$125.83 M
|
$116.50 M
|
$90.31 M
|
$71.10 M
|
$44.17 M
|
$41.06 M
|
$32.19 M
|
$28.03 M
|
$16.80 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$119.80 M
|
$125.83 M
|
$116.50 M
|
$90.31 M
|
$71.10 M
|
$44.17 M
|
$41.06 M
|
$32.19 M
|
$28.03 M
|
$16.80 M
|
| Other Expenses |
-$15.92 M
|
-$10.29 M
|
-$8.98 M
|
-$7.57 M
|
-$6.89 M
|
-$150.41 M
|
-$108.41 M
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$492.74 M
|
$581.86 M
|
$542.59 M
|
$502.71 M
|
$294.01 M
|
$44.17 M
|
$41.06 M
|
$121.30 M
|
$95.67 M
|
$48.64 M
|
| Cost And Expenses |
$508.66 M
|
$592.14 M
|
$551.57 M
|
$510.29 M
|
$300.90 M
|
$194.58 M
|
$149.47 M
|
$121.30 M
|
$95.67 M
|
$48.64 M
|
| Interest Income |
$29.20 M
|
$47.81 M
|
$49.83 M
|
$8.54 M
|
$1.28 M
|
$2.35 M
|
$6.84 M
|
$5.53 M
|
$2.01 M
|
$525.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$15.92 M
|
$10.29 M
|
$8.98 M
|
$7.57 M
|
$6.89 M
|
$6.31 M
|
$5.59 M
|
$4.46 M
|
$2.99 M
|
$1.10 M
|
| EBITDA |
-$396.77 M |
-$523.98 M |
-$506.32 M |
-$450.59 M |
-$260.96 M |
-$130.27 M |
-$100.78 M |
-$86.41 M |
-$66.56 M |
-$31.06 M |
| EBITDA Ratio |
-5.86
|
-9.05
|
-13.96
|
-8.65
|
-7.9
|
-2.25
|
-2.34
|
-2.84
|
-2.55
|
-1.88
|
| Operating Income Ratio |
-6.52
|
-9.23
|
-14.21
|
-8.79
|
-8.1
|
-2.36
|
-2.47
|
-2.99
|
-2.66
|
-1.95
|
| Total Other Income/Expenses Net |
$28.30 M
|
$15.24 M
|
$34.10 M
|
-$16.02 M
|
-$42.00 K
|
$2.35 M
|
$6.84 M
|
$5.53 M
|
$2.01 M
|
$525.00 K
|
| Income Before Tax |
-$412.69 M
|
-$519.02 M
|
-$481.19 M
|
-$474.19 M
|
-$267.89 M
|
-$134.23 M
|
-$99.53 M
|
-$85.34 M
|
-$67.54 M
|
-$31.63 M
|
| Income Before Tax Ratio |
-6.1
|
-8.97
|
-13.27
|
-9.1
|
-8.1
|
-2.31
|
-2.31
|
-2.8
|
-2.59
|
-1.92
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$412.69 M
|
-$519.02 M
|
-$481.19 M
|
-$474.19 M
|
-$267.89 M
|
-$134.23 M
|
-$99.53 M
|
-$85.34 M
|
-$67.54 M
|
-$31.63 M
|
| Net Income Ratio |
-6.1
|
-8.97
|
-13.27
|
-9.1
|
-8.1
|
-2.31
|
-2.31
|
-2.8
|
-2.59
|
-1.92
|
| EPS |
-3.81 |
-5.25 |
-5.42 |
-6.16 |
-3.78 |
-2.4 |
-1.96 |
-1.98 |
-1.88 |
-0.91 |
| EPS Diluted |
-3.81 |
-5.25 |
-5.42 |
-6.16 |
-3.78 |
-2.4 |
-1.96 |
-1.98 |
-1.88 |
-0.91 |
| Weighted Average Shares Out |
$108.38 M
|
$98.85 M
|
$88.77 M
|
$76.97 M
|
$70.89 M
|
$55.99 M
|
$47.25 M
|
$43.07 M
|
$36.01 M
|
$34.62 M
|
| Weighted Average Shares Out Diluted |
$108.38 M
|
$98.85 M
|
$88.77 M
|
$76.97 M
|
$70.89 M
|
$55.99 M
|
$47.25 M
|
$43.07 M
|
$36.01 M
|
$34.62 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
